Uveitis Therapeutics Analysis 2019 – Clinical Trials, Patents and Developments

Press Release

Uveitis therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Uveitis refers to a group of disorders that lead to inflammation in eyes and damages their tissues. The disease not only affects uvea, which is the middle layer of the eye, but also affects retina, vitreous humor, optic nerve, and iris. In severe cases, uveitis may lead to partial or complete loss of vision. Some of the commonly occurring symptoms of the disease include blurred vision, floating spots in eye, redness, pain, diminished pupil, headache, and photophobia. Uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis, and pan-uveitis.

Request for sample copy of this report at: https://www.pharmaproff.com/request-sample/1229

According to the research findings, majority of pipeline drug candidates are being developed for topical administration. It has been observed that this route possesses reproducible effects. Moreover, drugs administered by this route are less invasive as compared to other routes of administration.

Panoptes Pharma Ges.m.b.H, Gilead Sciences Inc., Santen Pharmaceutical Co. Ltd., Aldeyra Therapeutics Inc., Novartis International AG, Bristol-Myers Squibb Company, AbbVie Inc., Allergan Inc., Bausch Health Companies Inc., Galapagos NV, NovelMed Inc., Mitotech, and Clearside Biomedical Inc. are some of the key players involved in the development of therapeutic drugs indicated for the treatment of uveitis.

Uveitis Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This post was originally published on Financial Sector

Comments are closed.